IQVIA Holdings Inc. - IQV STOCK NEWS

In 2022, global clinical trial activity showed resilience with a 1% decline in non-COVID trials compared to 2021, while COVID-19 trials fell from 10% to 6% of total trials. A report from the IQVIA Institute revealed an 8% increase in non-COVID trial activity from 2019 levels, along with a 27% rise in clinical development productivity, marking a reversal of a 10-year downward trend. Total R&D spending by the largest pharmaceutical companies reached a record $138 billion, up 1.7% from 2021. Despite positive trends, there is concern over declining representation of Black/African American and Hispanic patients in clinical trials.

IQVIA Holdings Inc. (NYSE:IQV) has announced that Ron Bruehlman, the executive vice president and chief financial officer, will present at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023, at 9:30 a.m. ET. A live audio webcast of the presentation will be accessible via the IQVIA Investor Relations website, with a replay available later the same day. IQVIA is recognized for its advanced analytics, technology solutions, and clinical research services, operating in over 100 countries and employing approximately 86,000 individuals.

IQVIA has released its 2022 Environmental, Social, and Governance (ESG) Report, highlighting its commitment to environmental sustainability and public health improvement. The report details progress towards achieving net-zero greenhouse gas emissions, including a 22% reduction in market-based emissions per employee. Employee engagement remains strong, with over 80% of staff feeling aligned with IQVIA's mission. The company also maintained its diversity efforts, with women representing 60% of its workforce. Additionally, IQVIA was recognized on FORTUNE’s World's Most Admired Companies™ list for the sixth consecutive year, ranking first in multiple categories.

IQVIA reported strong financial results for Q4 2022 and the full year, with revenue of $3,739 million for Q4 and $14,410 million for the year. GAAP Net Income was $227 million for Q4 and $1,091 million for the year. Adjusted EBITDA was $920 million for Q4, a 11.1% increase year-over-year. The company recorded a book-to-bill ratio of 1.51x for Q4 and 1.36x for 2022. Looking ahead, IQVIA forecasts 2023 revenue between $15,150 million and $15,400 million, anticipating growth of 5.1% to 6.9%.

IQVIA (NYSE:IQV) has announced a collaboration with Alibaba Cloud to enhance technology solutions for the life sciences sector in Mainland China. This partnership will utilize Salesforce and IQVIA's Orchestrated Customer Engagement suite, adhering to local data residency laws. The collaboration aims to improve customer engagement for life sciences clients, allowing them to better serve their customers and patients in China. Executives from both companies expressed optimism about accelerating the introduction of these solutions, indicating a strong commitment to local compliance and technological advancement.

IQVIA Holdings Inc. (NYSE: IQV) will announce its fourth-quarter and full-year 2022 financial results on February 10, 2023, before market opens. The management team will host a conference call at 9:00 a.m. Eastern Time the same day. Investors can access the earnings release and related financial information on the IQVIA Investor Relations website. To participate in the call, prior registration is required. A replay of the webcast will be available two hours post-event. IQVIA is a leading global provider of analytics, technology solutions, and clinical research services, employing approximately 86,000 staff across over 100 countries.

The IQVIA Institute for Human Data Science reports that global spending on medicines is projected to reach $1.9 trillion by 2027, with a growth rate of 3-6% driven by new drug launches. The cumulative pharmaceutical market is expected to increase by $500 billion due to COVID-19, primarily from vaccines. Oncology spending will rise to $370 billion by 2027. Specialty medicines will account for 43% of global spending, while biotech spending will reach 35% by 2027. Increased drug access primarily in Latin America, Asia, and Africa contrasts with slow growth in North America and Europe.

Lasso, an IQVIA business, has expanded its Measurement Suite by integrating IQVIA's AIM XR, granting over 4,000 medical publishers access to enhanced insights on campaign reach and effectiveness.

This integration aims to simplify audience and campaign measurement for healthcare publishers, improving efficiency and breaking down barriers to return on investment.

With real-world impact studies and sales analysis capabilities, the initiative enhances healthcare communications and supports better decision-making and patient care.